Metrics as of 10/16/2026, 08:34 AM (Berlin time), refresh in progress.
ProKidney Stock
ProKidney Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Bruce Culleton
- Employees
- 231
- Market cap
- $489 M
- IPO
- 30/06/2021
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical…
ProKidney stock: price history
1D
-1.0%
1W
-12.3%
1M
-16.4%
6M
-25.4%
YTD
-35.0%
1Y
-54.1%
2Y
-15.9%
5Y
-85.3%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~28% weaker price swings than usual
Ask the agents about ProKidney
Analyst assessment of ProKidney
PRICE TARGET LOW
US$3.00
CONSENSUS
US$4.67
MEDIAN
US$5.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
6
BUY
1
HOLD
1
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 18/05/2026
ProKidney stock metrics
P/E
-2.55
P/B
-0.31
EV/EBITDA
-2.61
RETURN ON EQUITY
3.2%
NET MARGIN
-18,948.0%
DEBT/EQUITY
-0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
73.4%
FLOAT SHARES
108,811,415
AVG. DAILY VOLUME (30D)
1,573,631
Insider transactions (SEC)
Pereira Brian JG
Pereira Brian JG
Pereira Brian JG
Pereira Brian JG
Pereira Brian JG
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about ProKidney stock
What does ProKidney do?
ProKidney Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Bruce Culleton, the company employs around 231 people.
The IPO was on 30/06/2021; the stock trades on NASDAQ under the ticker PROK.
What do analysts say about ProKidney stock?
8 analysts rate the stock, the consensus is Buy (as of 18/05/2026).
The average price target is US$4.67, ranging from US$3.00 to US$6.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does ProKidney report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -28% stronger than usual.
Does ProKidney pay a dividend?
No, ProKidney currently does not pay a dividend.
Which stocks are comparable to ProKidney?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get ProKidney stock analyzed?
Clicking "Analyze stock" lets five strategies assess ProKidney against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.